ACRV – acrivon therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.
Form 8-K Acrivon Therapeutics, For: Mar 11
Form 4 Acrivon Therapeutics, For: Mar 01 Filed by: Peterson Katharine
Form 4 Acrivon Therapeutics, For: Mar 01 Filed by: Miller Mary
Form 4 Acrivon Therapeutics, For: Mar 01 Filed by: Holm-Jorgensen Rasmus
Form 4 Acrivon Therapeutics, For: Mar 01 Filed by: Gamelin Erick
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.